The information in this section is intended for visitors outside the United States.
Gilead Sciences Announces Third Quarter 2015 Dividend
Gilead Sciences Announces Second Quarter 2015 Financial Results
Gilead Announces Executive Promotions
Gilead Sciences to Release Second Quarter 2015 Financial Results on Tuesday, July 28, 2015
Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF)
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Harvoni®, the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C
2014 Annual Review